earnings
confidence high
sentiment neutral
materiality 0.75
Gilead Q1 revenue $6.6B (+3%), non-GAAP EPS $2.12 (+4%), GAAP EPS $0.02 due to $2.7B impairment
GILEAD SCIENCES, INC.
2022-Q1 EPS reported
$0.02
revenue$6,590,000,000
- GAAP diluted EPS $0.02 vs $1.37 Q1 2021 due to $2.7B IPR&D impairment; non-GAAP EPS $2.12, +4% YoY.
- Biktarvy sales $2.2B (+18%), oncology sales $420M (+60%) led by Trodelvy $146M (+103%) and cell therapy $274M (+43%).
- Veklury sales $1.5B (+5%); HIV total $3.7B (+2%); HCV sales $399M (-22%).
- Updated GAAP EPS guidance to $3.00-$3.50 from $4.70-$5.20; non-GAAP EPS and revenue guidance unchanged.
- Cash $6.8B; operating cash flow $1.8B includes $1.25B legal settlement; $725M Arcus opt-in payment, $352M buybacks.